Literature DB >> 30851458

Warfarin versus aspirin prevents portal vein thrombosis after laparoscopic splenectomy and azygoportal disconnection: A randomized clinical trial.

Dou-Sheng Bai1, Bing-Lan Xia2, Chi Zhang1, Jing Ye3, Jian-Jun Qian1, Sheng-Jie Jin1, Guo-Qing Jiang4.   

Abstract

INTRODUCTION: Portal vein system thrombosis (PVST) is a common, potentially life-threatening complication after splenectomy. The optimal recognized anticoagulation drugs for preventing PVST in cirrhotic patients after splenectomy remain unclear. The aim of this study is to evaluate the safety and efficacy of warfarin in preventing PVST after laparoscopic splenectomy and azygoportal disconnection (LSD).
METHODS: In this randomized controlled single-center study, 80 cirrhotic patients who underwent LSD were randomly assigned to 2 years of treatment with either warfarin (n = 40) or aspirin (n = 40). The primary outcome was prevention of PVST. Sonographers and radiologists who assessed outcomes were blinded to group assignments. Intention-to-treat analysis was performed.
RESULTS: During the first year, excluding two patients withdrawing from the study, 15 of the 39 warfarin-treated patients (38.5%) and five of the 39 aspirin-treated patients (12.8%) did not develop PVST (P = 0.010). The incidence of PVST in the first 2 postoperative years was significantly lower in the warfarin group than in the aspirin group (F = 7.360, P = 0.008). The warfarin group in paired within-group comparisons had significantly greater improvements in total bilirubin and albumin levels at baseline versus at 6 months postoperatively and in creatinine levels at baseline versus at 12, 18, and 24 months postoperatively respectively (all P < 0.05). In contrast, those paired comparisons of the aspirin group showed no significant differences (all P > 0.05).
CONCLUSIONS: Warfarin therapy was safe and effective and significantly reduced the risk of PVST after LSD, compared with aspirin treatment. Warfarin treatment was associated with better liver function protection and renal function improvement than aspirin treatment.
Copyright © 2019 IJS Publishing Group Ltd. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Laparoscopy; Liver cirrhosis; Portal hypertension; Thrombosis; Warfarin

Mesh:

Substances:

Year:  2019        PMID: 30851458     DOI: 10.1016/j.ijsu.2019.02.018

Source DB:  PubMed          Journal:  Int J Surg        ISSN: 1743-9159            Impact factor:   6.071


  5 in total

1.  Splanchnic Vein Thrombosis in Liver Cirrhosis After Splenectomy or Splenic Artery Embolization: A Systematic Review and Meta-Analysis.

Authors:  Yanyan Wu; Hongyu Li; Tiansong Zhang; Zhaohui Bai; Xiangbo Xu; Giovanni Battista Levi Sandri; Le Wang; Xingshun Qi
Journal:  Adv Ther       Date:  2021-03-09       Impact factor: 3.845

2.  Clinical effects of cluster technology optimization and innovations on laparoscopic splenectomy and azygoportal disconnection: a single-center retrospective study with 500 consecutive cases.

Authors:  Long-Fei Wu; Dou-Sheng Bai; Rong-Hua Gong; Sheng-Jie Jin; Chi Zhang; Bao-Huan Zhou; Jian-Jun Qian; Guo-Qing Jiang
Journal:  Surg Endosc       Date:  2022-03-07       Impact factor: 3.453

Review 3.  Safety and Efficacy of Anticoagulation in Patients with Cirrhosis: A Meta-Analysis.

Authors:  Huan Chen; Jiaming Lei; Sicheng Liang; Gang Luo; Mingming Deng; Muhan Lü
Journal:  Can J Gastroenterol Hepatol       Date:  2021-04-21

4.  Does splenectomy significantly improve the prognosis of hepatocellular carcinoma patients with hypersplenism? A systematic review and meta-analysis.

Authors:  Xue-Bing Shi; Jin-Kai Feng; Jing-Han Wang; Xiao-Qing Jiang
Journal:  Ann Transl Med       Date:  2021-04

5.  Rivaroxaban versus low-molecular weight heparin plus warfarin prevents portal vein system thrombosis after splenectomy and pericardial devascularization: A randomized clinical trial.

Authors:  Wei Yao; Yongan Feng; Ting Liu; Wujun Li; Mei Zhang; Yingmin Yao; Shengli Wu
Journal:  EXCLI J       Date:  2021-03-04       Impact factor: 4.068

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.